<p>Mass spectrometry (MS) alone or coupled with high-performance liquid chromatography (HPLC) or gas chromatography (GC) is a versatile analytical tool that is routinely employed for identification of unknown compounds in complex mixtures. MS operates by separating ionized analytes based on their mass-to-charge (<i>m/z</i>) ratios. If the analyte can be ionized without complete fragmentation, MS provides molecular weight information and, if performed at high resolution, elemental compositions for the ionized analytes. Tandem mass spectrometry (MSⁿ, n <u>></u> 2 where each MS step corresponds to an ion isolation or separation event) also provides structural information of ionized analytes. With this approach, structural information of the ionized analytes is obtained by isolating the ionized analytes of interest and subjecting them to fragmentation experiments, such as collision-activated dissociation (CAD). The ions of interest can also be isolated and allowed to react with gaseous molecules to generate product ions (ion-molecule reactions). </p> The experiments described in this dissertation focused on the development of tandem mass spectrometry methods based on CAD and/or gas-phase ion-molecule reactions for the differentiation of acyl, <i>N</i>- and <i>O</i>-glucuronide drug metabolites and for identification of primary carbamates as potentially mutagenic impurities. Further, by using a previously published method titled Distillation, Precipitation, Fractionation Mass Spectrometry (DPF MS), the chemical compositions of five crude oil samples, including heavy, medium, and light crude oils with different API gravities, were determined. Additionally, the gravimetric percentages of different compound classes found in these crude oils are reported as well as the correlations found between API gravities and the chemical compositions of crude oils.

Les cucurbitacines et les parabènes sont des substances d'origine naturelle appartenant à la famille des triterpéniques cycliques et des esters de l'acide-hydroxybenzoïque, respectivement. Ils sont connus pour posséder chez l'homme plusieurs effets pharmacologiques potentiellement intéressants. Le but de ce travail est d'étudier la biotransformation d'une série de trois cucurbitacines et de cinq parabènes dans le foie humain in vitro, essentiellement par glucuronoconjugaison et hydrolyse et caractériser l'effet cytotoxique des cucurbitacines sur une lignée cellulaire du chondrosarcome humain SW 1353. Les résultats ont montré que les cucurbitacines I et D sont plus cytotoxiques que la cytochalasine D vis-à-vis SW 1353 et entraînent l'apoptose des cellules après 12h de traitement à 1 µM alors que la cucurbitacine E présente une cytotoxicité à 10 µM. L'étude in vitro de biotransformation chez l'homme montre que les cucurbitacines sont surtout sulfo- et glucuronoconjuguées (méthodes radiochimiques) par les isoformes de la famille 1A essentiellement. La cucurbitacine E est également activement hydrolysées (Km 22 µM et Vmax 571 nmol/mg /min) en cucurbitacine I dans le foie humain. Par contre, ces substances sont très faiblement hydroxylées. Les acides oléanolique, ursolique et l'érythrodiol, de structure apparentée aux cucurbitacines, sont aussi glucuronoconjuguées au même taux dans les microsomes hépatiques humains mais avec des affinités 100 fois plus élevées. Les parabènes sont rapidement hydrolysés par des estérases dans les microsomes hépatiques humains en acide 4-hydroxybenzoïque, et leur hydrolyse diminue avec la longueur de la chaîne alkyle. Les parabènes, l'acide caféique, le tyrosol et l'hydroxytyrosol, de structure apparentée aux parabènes, sont activement glucuronoconjuguées par les UGTs des familles 1A et 2B. Cependant, l?acide 4-hydroxybenzoïque n'est pas un bon substrat pour les UGTs / Cucurbitacins and parabens are natural compounds belonging to cyclic triterpenoid and alkyl ester of 4-hydroxybenzoic acid, respectively. They are known for their potential valuable pharmacological effects. The aim of this work was to study the biotransformation of a series of three cucurbitacins and six parabens in human liver, in vitro, essentially by glucuronidation and hydrolysis reactions, and by comparision with other natural substances structurally related, and to characterize the cytotoxicity effect of cucurbitacins on a human chondrosarcoma cell line, SW 1353. The results showed that cucurbitacins I and D showed more cytotoxicity than cytochalasin D and led to cell apoptosis after 12h of treatment at 1 ?M. Cucurbitacin E showed its cytotoxic effect at 10 µM. The in vitro study of cucurbitacins biotransformation in man showed that these substances are sulfated, glucuronidated (radiochemical methods). Moreover, cucurbitacin E was actively hydrolyzed (Km 22 µM and Vmax 571 nmol/mg protein/min) leading to cucurbitacin I in man liver. On the other hand, they are weakly hydroxylated. Oleanolic acid, ursolic acid and erythrodiol, chemically related to cucurbitacins, were glucuronidated at the same rate in human liver microsomes, however, with affinities 100 times greater. Parabens were quickly hydrolyzed in human liver microsomes by esterases and hydrolysis decreased with side chain length. Parabens, caffeic acid, tyrosol and hydroxytyrosol were actively glucuronidated by the UGTs of both families 1A and 2B. However, p-hydroxybenzoic acid is not a good substrate for UGTs

The bioavailability of a drug can be described as the fraction of an orally administered dose that reaches the systemic circulation and is often limited by first-pass metabolism in the gut and the liver. It is important to have knowledge about these processes since the systemic blood drug concentration is tightly connected to the effect of the drug. The general aim of this project was to quantitatively examine the role of the intestine in relation to the liver in first-pass metabolism of orally administered drugs. The first-pass metabolism of verapamil and raloxifene was investigated in detail with in vivo, in vitro and simulation studies, using the pig as an experimental model. The intestine contributed to the same extent as the liver to first-pass metabolism of R/S-verapamil in vivo in pigs. The S-isomer of verapamil was found in lower plasma concentrations compared to the R-isomer after oral dosing. The in vitro metabolism of verapamil in pig and human liver showed interspecies similarity and indicated equal intrinsic clearance for R- and S-verapamil. Through physiologically based pharmacokinetic modeling the stereoselectivity was explained by a combination of several processes, including enantioselective plasma protein binding, blood-to-plasma partition, and gut and liver tissue distribution. For raloxifene the intestine was the dominating organ in first-pass glucuronidation in vivo in pigs. Furthermore, the raloxifene concentration entering the intestine or the dose administered in the gut did not influence the plasma PK of raloxifene and indicated that the intestinal metabolism was not saturable with clinical relevant doses. For both verapamil and raloxifene, a time-dependent hepatic metabolism was noted with major consequences to the pharmacokinetic of the drugs. This project has pointed out the importance of intestinal metabolism in the overall first-pass extraction of drugs and indicates that intestinal metabolism should be considered and evaluated early in drug development.

No description available.

Au cours de cette thèse, nous montrons que l’obésité est un facteur de variabilité pharmacodynamique et pharmacocinétique de la morphine. En particulier, l’absorption et l’exposition à la morphine orale augmentent de façon significative après chirurgie de type bypass gastrique. Nous démontrons le rôle du contenu entérocytaire en transporteur d’efflux P-gp, dans la détermination de l’absorption et de l’exposition à la morphine. / In this thesis, we show that obesity is a factor of pharmacodynamic and pharmacokinetic morphine variability. In particular, absorption and exposure to oral morphine increases significantly after gastric bypass surgery . We demonstrate the role of enterocyte content of efflux transporter P-gp in determining the absorption and exposure to morphine.

Introduction Estrogen-induced cholestasis is a disease characterized by a failure of bile flow and bile production. It can develop in women after oral contraceptives use, hormone replacement therapy or during pregnancy. The estrogen metabolism is a complex process leading to formation of metabolites with different biological activities. It takes place primarily in the liver (Phase I and Phase II including hydroxylation, methylation, sulfation and glucuronidation). The enzymes from UDP-glucuronosyltransferases family , abbreviated UGT, are responsible for the glucuronidation of estrogens. Aims The objective of my work is to define estrogen metabolism and gene expression of UGT1A1, CYP1A2 and SULT1A1 and characterize cholestatic liver damage in the UGT1A1 deficient rat strain (Gunn rats) compared to rats with normal enzyme activity and try to define possible mechanisms responsible for the liver damage. Methods Adult female Gunn and corresponding heterozygous rats were treated with ethinylestradiol (EE, 5 mg/kg body weight SC) for 5 days, while control rats received propanediol (vehicle). Day six, the animals were sacrificed and plasma and liver tissue were collected for analysis. Markers of cholestasis and liver damage ALP, AST, ALT and bilirubin were determined using an automatic analyzer, total...

The general aim of this thesis was to improve the understanding of the in vivo pharmacokinetics and, in particular, the metabolism of finasteride, a 5α-reductase inhibitor used in the treatment of enlarged prostate glands and male pattern baldness. CYP3A4 has been identified as the major enzyme involved in the sequential metabolism of finasteride to ω-OH finasteride (M1) and ω-COOH finasteride (M3). The consequences of induced and inhibited metabolism on the pharmacokinetics of finasteride and its metabolites were investigated in humans and pigs. Both studies included bile collection. The collected human and pig samples were used for the metabolite identification. As expected, induced metabolism led to reduced plasma exposure of finasteride and inhibited metabolism had the opposite effect. The interactions were investigated in detail and included examination of the biliary pharmacokinetics of finasteride and its metabolites. In pigs, the study included monitoring of the hepatic extraction over time, deconvolution and the development of a semi-physiological model for comparison of the effects on the gut wall and liver metabolism. For M3, the concentration ratios of bile to plasma and the renal clearance indicated that carrier-mediated processes are involved in the biliary and urinary excretion. This was not, however, the case for finasteride. The metabolite, M1, could not be quantified either in humans or pigs. Instead, two other OH metabolites, M1 isomers, were identified in humans. These metabolites were found to undergo glucuronide conjugation. In humans, one glucuronide was identified intact and in pigs, both glucuronides were identified intact in bile and in urine. In addition, a glucuronide of M3 was identified in human bile. In conclusion, advances have been made in the understanding of the pharmacokinetics of finasteride, in particular in relation to the metabolism. Hopefully, the findings of this comprehensive investigation can be applied to other drugs and novel chemical entities.

Au cours de cette thèse, nous montrons que l'obésité est un facteur de variabilité pharmacodynamique et pharmacocinétique de la morphine. En particulier, l'absorption et l'exposition à la morphine orale augmentent de façon significative après chirurgie de type bypass gastrique. Nous démontrons le rôle du contenu entérocytaire en transporteur d'efflux P-gp, dans la détermination de l'absorption et de l'exposition à la morphine.

The goal of the first project was to evaluate strategies for determining the in vitro intrinsic clearance (CLint) of dextrorphan (DR) as metabolized by the UGT2B7 enzyme to obtain dextrorphan glucuronide (DR-G). A direct injection liquid chromatography-mass spectrometry (LC-MS) method was used to monitor products using the pseudo-first-order (PFO) model. Standard enzymatic incubations were also quantified using LC-MS. These data were fit utilizing both PFO and Michaelis-Menten (MM) models to determine estimates of kinetic parameters. The CLint was determined to be 0.28 (± 0.08) µL/min/mg protein for a baculovirus insect cell-expressed UGT2B7 enzyme. This is the first confirmation that dextrorphan is specifically metabolized by UGT2B7 and the first report of these kinetic parameters. Simulated chromatographic data were used to determine the precision and accuracy in the estimation of peak volumes in comprehensive two-dimensional liquid chromatography (2D-LC). Volumes were determined both by summing the areas in the second dimension chromatograms via the moments method and by fitting the second dimension areas to a Gaussian peak. When only two second dimension signals are substantially above baseline, the accuracy and precision are poor because the solution to the Gaussian fitting algorithm is indeterminate. The fit of a Gaussian peak to the areas of the second dimension peaks is better at predicting the peak volume when there are at least three second dimension injections above the limit of detection. Based on simulations where the sampling interval and sampling phase were varied, we conclude for well-resolved peaks that the optimum precision in peak volumes in 2D separations will be obtained when the sampling ratio is approximately two. This provides an RSD of approximately 2 % for the signal-to-noise (S/N) used in this work. The precision of peak volume estimation for experimental data was also assessed, and RSD values were in the 4-5 % range. We conclude that the poorer precision found in the 2D-LC experimental data as compared to 1D-LC is due to a combination of factors, including variations in the first dimension peak shape related to undersampling and loss in S/N due to the injection of multiple smaller peaks onto the second dimension column.